Trust Co of Kansas Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

Trust Co of Kansas cut its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 5.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,018 shares of the biopharmaceutical company’s stock after selling 592 shares during the period. Pfizer comprises approximately 0.3% of Trust Co of Kansas’ holdings, making the stock its 28th largest position. Trust Co of Kansas’ holdings in Pfizer were worth $482,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Saxon Interests Inc. lifted its holdings in Pfizer by 12.9% in the third quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock valued at $367,000 after acquiring an additional 951 shares during the period. Platte River Wealth Advisors LLC increased its holdings in Pfizer by 62.8% during the third quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 4,905 shares during the last quarter. Accuvest Global Advisors boosted its stake in shares of Pfizer by 16.6% during the 3rd quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock worth $569,000 after acquiring an additional 1,848 shares during the last quarter. Ledyard National Bank raised its holdings in Pfizer by 0.5% in the 3rd quarter. Ledyard National Bank now owns 364,223 shares of the biopharmaceutical company’s stock worth $15,938,000 after purchasing an additional 1,654 shares during the period. Finally, Oak Asset Management LLC purchased a new position in Pfizer during the third quarter valued at $723,000. 67.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. UBS Group set a $45.00 price objective on Pfizer in a research note on Tuesday. The Goldman Sachs Group upgraded shares of Pfizer from a “neutral” rating to a “buy” rating and upped their price target for the stock from $47.00 to $60.00 in a research report on Tuesday, December 13th. Wells Fargo & Company cut shares of Pfizer from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $54.00 to $50.00 in a research note on Tuesday, January 17th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 1st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price target on the stock in a report on Tuesday, February 7th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $50.75.

Pfizer Trading Up 1.0 %

PFE stock opened at $40.28 on Thursday. The firm has a market cap of $226.34 billion, a PE ratio of 7.35, a price-to-earnings-growth ratio of 1.31 and a beta of 0.64. The firm has a fifty day moving average price of $43.67 and a 200 day moving average price of $46.11. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22. Pfizer Inc. has a fifty-two week low of $39.23 and a fifty-two week high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last posted its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. During the same period in the previous year, the firm posted $1.08 EPS. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.